Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Spyre Therapeutics, Inc. SYRE NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
35/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$51.00
-26.1%

Spyre Therapeutics, Inc. (SYRE) is a Biotechnology company in the Healthcare sector, currently trading at $68.99. It has a SharesGrow Score of 34/100, indicating a weak investment profile with 2 out of 7 criteria passed.

Analyst consensus target is SYRE = $51 (-26.1% upside).

Valuation: SYRE trades at a trailing Price-to-Earnings (P/E) of -115.5 (S&P 500 average ~25).

Net income is $155M (loss), growing at -80.1%/yr. Net profit margin is 0% (thin). Gross margin is -8.8% (-24.5 pp trend).

Balance sheet: total debt is $0 against $715M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 13.25 (strong liquidity). Debt-to-assets is 0%. Total assets: $778M.

Analyst outlook: 6 / 6 analysts rate SYRE as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 19/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 12/100 (Fail), Future 64/100 (Pass), Income ?/100 (Fail).

$51.00
▼ 26.08% Downside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for Spyre Therapeutics, Inc., the average price target is $51.00, with a high forecast of $53.00, and a low forecast of $49.00.
Highest Price Target
$53.00
Average Price Target
$51.00
Lowest Price Target
$49.00

SYRE SharesGrow Score Overview

42/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 19/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 12/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SYRE

✗
VALUE Fail
19/100
SYRE trades at a trailing Price-to-Earnings (P/E) of -115.5 (S&P 500 average ~25). Forward PEG -16.12 — Peter Lynch undervalued (≤1.0). Trailing PEG 2.2. Analyst consensus target is $51, implying -26.1% from the current price $69. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
SYRE: -81%/yr revenue is, -80.1%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet SYRE: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 13.25 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
12/100
SYRE: Gross margin is -8.8% (-24.5 pp trend), $4B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 12/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 6 / 6 analysts rate SYRE as buy (100%). Analyst consensus target is $51 (-26.1% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range10.91-51.06
Volume4.04M
Avg Volume (30D)833.66K
Market Cap$4.17B
Beta (1Y)2.94
Share Statistics
EPS (TTM)-1.98
Shares Outstanding$346.05M
IPO Date2016-04-07
Employees73
CEOCameron Turtle
Financial Highlights & Ratios
Gross Profit$-171.65M
EBITDA$-209.56M
Net Income$-155.2M
Operating Income$-209.56M
Total Cash$756.53M
Net Debt$-85.72M
Total Assets$777.78M
Price / Earnings (P/E)-34.8
Analyst Forecast
1Y Price Target$51.00
Target High$53.00
Target Low$49.00
Upside-26.1%
Rating ConsensusBuy
Analysts Covering6
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS00773J2024

Price Chart

Track all markets on TradingView
SYRE
Spyre Therapeutics, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
10.91 52WK RANGE 51.06

People Also View

CLDX
CLDX
Celldex Therapeutics, Inc.
$33.87
+1.62%
 ZYME
ZYME
Zymeworks Inc.
$27.73
+2.78%
 IMNM
IMNM
Immunome, Inc.
$23.39
+2.14%
 PHVS
PHVS
Pharvaris N.V.
$29.14
+1.60%
 NTLA
NTLA
Intellia Therapeutics, Inc.
$14.94
+1.08%
 ARDX
ARDX
Ardelyx, Inc.
$6.30
-0.47%
 WVE
WVE
Wave Life Sciences Ltd.
$7.59
+2.71%
 MAZE
MAZE
Maze Therapeutics, Inc.
$26.85
-3.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message